XML 19 R7.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Summary of Significant Accounting Policies | 9 Months Ended
--- | ---
Sep. 30, 2022
Accounting Policies [Abstract] |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2021, except as described below. Short-Term Investments The Company's held-to-maturity short-term investments in U.S. government securities are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment. Any impairment that is not deemed to be temporary is recognized in the period identified. Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net loss per common share for the three and nine months ended September 30, 2022 includes the outstanding pre-funded warrants to purchase 11,666,667 and 3,200,000 shares of common stock issued in the April 2022 Public Offering and December 2020 public offering, respectively. The outstanding pre-funded warrants to purchase 3,200,000 shares of common stock issued in the December 2020 public offering were included in the three and nine months ended September 30, 2021. Diluted net loss per common share for the three and nine months ended September 30, 2022 and 2021 was determined as follows (in thousands, except share and per share amounts):
| Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Net loss | $ | (29,584 | ) |  | $ | (605 | ) |  | $ | (48,380 | ) |  | $ | (3,623 | )
Dilutive effect of warrant liability |  | — |  |  |  | — |  |  |  | — |  |  |  | (15,719 | )
Dilutive effect of convertible debt |  | — |  |  |  | (988 | ) |  |  | — |  |  |  | — |
Net loss allocated to common shares | $ | (29,584 | ) |  | $ | (1,593 | ) |  | $ | (48,380 | ) |  | $ | (19,342 | )
Weighted average common shares outstanding – basic |  | 47,503,821 |  |  |  | 26,616,628 |  |  |  | 40,965,908 |  |  |  | 26,147,658 |
Dilutive effect of warrant liability |  | — |  |  |  | — |  |  |  | — |  |  |  | 178,348 |
Dilutive effect of convertible debt |  | — |  |  |  | 1,138,200 |  |  |  | — |  |  |  | — |
Weighted average common shares outstanding – diluted |  | 47,503,821 |  |  |  | 27,754,828 |  |  |  | 40,965,908 |  |  |  | 26,326,006 |
Net loss per share – diluted | $ | (0.62 | ) |  | $ | (0.06 | ) |  | $ | (1.18 | ) |  | $ | (0.73 | )
The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three and nine months ended September 30, 2022 and 2021, as the result would be anti-dilutive:
| Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Outstanding stock options |  | 2,125,002 |  |  |  | 1,643,506 |  |  |  | 2,125,002 |  |  |  | 1,643,506 |
Outstanding restricted stock units |  | 990,015 |  |  |  | 149,134 |  |  |  | 990,015 |  |  |  | 149,134 |
Warrants to purchase common stock associated with March 2018 public offering – Series 2 |  | 798,810 |  |  |  | 798,810 |  |  |  | 798,810 |  |  |  | 798,810 |
Warrants to purchase common stock associated with December 2019 public offering |  | — |  |  |  | 4,472,205 |  |  |  | — |  |  |  | 4,472,205 |
Warrants to purchase common stock associated with December 2020 public offering - Series 1 |  | — |  |  |  | 6,439,866 |  |  |  | — |  |  |  | — |
Warrants to purchase common stock associated with December 2020 public offering - Series 2 |  | 6,800,000 |  |  |  | 6,800,000 |  |  |  | 6,800,000 |  |  |  | 6,800,000 |
Warrants to purchase common stock associated with April 2022 Public Offering |  | 15,000,000 |  |  |  | — |  |  |  | 15,000,000 |  |  |  | — |
Warrants to purchase common stock associated with Loan Agreement |  | 198,819 |  |  |  | 170,410 |  |  |  | 198,819 |  |  |  | 170,410 |
Common stock associated with March 2019 Notes |  | 1,138,200 |  |  |  | — |  |  |  | 1,138,200 |  |  |  | 1,138,200 |
Warrants to purchase common stock associated with Danforth |  | 50,000 |  |  |  | — |  |  |  | 50,000 |  |  |  | — |
Total |  | 27,100,846 |  |  |  | 20,473,931 |  |  |  | 27,100,846 |  |  |  | 15,172,265 |
Reclassification of Prior Year Amounts Certain prior year amounts have been reclassified for consistency with the current year presentation. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its unaudited condensed consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its unaudited condensed consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI https://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration